One needs to play the long game here - share pricing this week,...

One needs to play the long game here - share pricing this week, next month, next year.....does it really matter. You are making an investment based on the work done by two of the greatest New Zealand medical scientists we have seen in years - Sir Peter Gluckman (Chief Science Advisor to the Prime Minister 2009-2018) and Distinguished Professor Dame Margaret Brimble. Couple this with the leadership of Jon Pilcher and the savvy Trevor Scott. Patience is needed as this is a very different situation than most of the other listed biotech wannabes. Trofinetide and especially NNZ-2591 - the work of Dame Margaret Brimble is what you are investing in. FDA approval is hardly an issue here so lets not get too stressed here.